On the (sulfo)glycomics front, we have focused particularly on sialylated glycans carrying Gal-6-O-sulfate and/or GlcNAc-6-O-sulfate modifications that can markedly enhance recognition by selected Siglecs. This is motivated by the emerging role of Siglecs as inhibitory immune checkpoints in peripheral immunity and in the central nervous system, where altered Siglec–glycan interactions are increasingly implicated in neuroinflammation and neurodegenerative disease (Siew et al., Mol Aspects Med, 2022). In collaboration with the Macauley laboratory, we applied detailed sulfoglycomic profiling to CHST1-overexpressing and glycogene-knockout cell systems to dissect the biosynthetic pathways that generate sulfated Siglec ligands. These studies showed how sulfotransferases, glycosyltransferases and the underlying glycan carriers act combinatorially to generate high-affinity Siglec-binding glycotopes (Jung et al., ACS Chem Biol, 2025).
In parallel, we have advanced negative-ion LC-MS/MS methods for sequencing highly sulfated polyLacNAc and keratan sulfate structures, which are particularly challenging because both chain length and positional sulfation must be resolved. In ovarian carcinoma, our workflow enabled direct characterization of low- and high-sulfated keratan sulfate, including O-glycans containing up to five LacNAc repeats and four sulfate groups, and helped establish structural distinctions associated with tumor subtype and prognosis (Hoshino et al., Glycobiology, 2024; Inoue et al., Lab Invest, 2024, supported by NSTC 112-2311-B-001-014-MY3). The broader utility of this approach was further illustrated in seal milk oligosaccharides, where our permethylation-based MS analysis uncovered exclusively branched polyLacNAc chains capped by either NeuAc or Fuc, extending up to 28 glycosyl residues and revealed that GlcNAc sulfation locally constrains adjacent galactose branching (Jin et al., Nat Comm, 2025). Together, these studies establish sulfoglycomics as a distinctive strength of our laboratory for resolving structural features that are easily missed by conventional glycomic workflows, and position us to connect sulfated glycan architecture with Siglec recognition, carcinoma biology and immune homeostasis across diverse biological systems.